This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Welcome to the new home for Guidelines

Summary for secondary care

Molecular Testing Strategies for Lynch Syndrome in People with Colorectal Cancer

This specialist Guidelines summary provides recommendations on using immunohistochemistry or microsatellite instability testing to guide further testing for Lynch syndrome in people with colorectal cancer.

This summary is intended for use in a secondary care setting by oncologists. Please refer to the full guideline for further information.

Molecular Testing Strategies Flowchart

Algorithm 1: Flowchart Showing Molecular Testing Strategies for Lynch Syndrome in People with Colorectal Cancer

Recommendations

  • Offer testing to all people with colorectal cancer, when first diagnosed, using immunohistochemistry for mismatch repair proteins or microsatellite instability testing to identify tumours with deficient DNA mismatch repair, and to guide further sequential testing for Lynch syndrome (see the next 2 recommendations below). Do not wait for the results before starting treatment
  • If using immunohistochemistry, follow the steps in table 1
  • If using microsatellite instability testing, follow the steps in table 2.
Table 1: Steps in the Immunohistochemistry Testing Strategy
StepDetails
Step 1Do an immunohistochemistry 4‑panel test for MLH1, MSH2, MSH6 and PMS2.
Step 2If the MLH1 immunohistochemistry result is abnormal, use sequential BRAF V600E and MLH1 promoter hypermethylation testing to differentiate sporadic and Lynch syndrome-associated colorectal cancers. First do a BRAF V600E test.If the MSH2, MSH6 or PMS2 immunohistochemistry results are abnormal, confirm Lynch syndrome by genetic testing of germline DNA.
Step 3If the BRAF V600E test is negative, do an MLH1 promoter hypermethylation test.
Step 4If the MLH1 promoter hypermethylation test is negative, confirm Lynch syndrome by genetic testing of germline DNA.
Table 2: Steps in the Microsatellite Instability Testing Strategy
StepDetails
Step 1Do a microsatellite instability test.
Step 2If the microsatellite instability test result is positive, use sequential BRAF V600E and MLH1 promoter hypermethylation testing to differentiate sporadic and Lynch syndrome-associated colorectal cancers. First do a BRAF V600E test.
Step 3If the BRAF V600E test is negative, do an MLH1 promoter hypermethylation test.
Step 4If the MLH1 promoter hypermethylation test is negative, confirm Lynch syndrome by genetic testing of germline DNA.
  • Healthcare professionals should ensure that people are informed of the possible implications of test results for both themselves and their relatives, and ensure that relevant support and information is available. Discussion of genetic testing should be done by a healthcare professional with appropriate training
  • Laboratories doing microsatellite instability testing or immunohistochemistry for mismatch repair proteins should take part in a recognised external quality assurance programme.

References


UP NEXT